Research from Frost & Sullivan breathes some life into the potential for generic drug makers...
Research from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil.
From other sites
at Nasdaq.com (Jan 6, 2015)
at Nasdaq.com (Jan 5, 2015)
at Nasdaq.com (Dec 30, 2014)
at Nasdaq.com (Nov 24, 2014)
at CNBC.com (Jan 4, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs